Results 31 to 40 of about 8,117 (271)

Successful Introduction of Benralizumab for Eosinophilic Ascites

Biomedicines
Eosinophilic ascites is a rare disorder, reported in both adult and pediatric patients, characterized by high eosinophil counts in the peritoneal fluid.
Nabil Belfeki, Nouha Ghriss, Souheil Zayet, Faten El Hedhili, Cyrus Moini, Guillaume Lefevre   +5 more
semanticscholar   +3 more sources

Early and Sustained Response to Benralizumab in Severe, Eosinophilic Asthma: A Real-World Observational Study. [PDF]

J Asthma Allergy
Purpose Although studies have evaluated benralizumab, a monoclonal IL-5 receptor α antibody in severe eosinophilic asthma (SEA), in real-world settings, additional evidence is needed to further characterize its effectiveness in specific patient ...
Stolz D, Schuoler C, Charbonnier F, Bridevaux PO, Jandus P, Leuppi JD, Pavlov N, Piecyk A, Rothe T.   +8 more
europepmc   +2 more sources

Efficacy and Safety of Biologics for Chronic Rhinosinusitis With Nasal Polyps: A Meta-Analysis of Real-World Evidence. [PDF]

Allergy
ABSTRACT Dupilumab, omalizumab, mepolizumab, and benralizumab have demonstrated good efficacy and safety in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP) in phase 3 randomised controlled trials (RCTs). With recent regulatory approvals, there has been a surge in real‐world studies (RWSs).
Cai S, Xu S, Zhao Y, Zhang L.
europepmc   +2 more sources

Single-center off-label benralizumab use for refractory hypereosinophilic syndrome demonstrates satisfactory safety and efficacy. [PDF]

EJHaem
Benralizumab is an interleukin 5‐receptor‐blocking drug registered for the treatment of eosinophilic asthma. It has proven efficient and safe in a small phase‐II trial in hypereosinophilic syndrome and is currently being investigated in a larger ...
Veltman Y, Aalbers AM, Hermans MAW, Mutsaers PGNJ.   +3 more
europepmc   +2 more sources

Predicting response to benralizumab in patients with COPD: a plain language summary of publication of the GALATHEA and TERRANOVA studies [PDF]

Therapeutic Advances in Respiratory Disease
Summary What is this summary about? ● This is a plain language summary of two articles originally published in The New England Journal of Medicine and The Lancet Respiratory Medicine .
Gerard J. Criner, Dave Singh, Alberto Papi, Maria Jison, Natalya Makulova, Vivian H. Shih, Laura Brooks, Peter N. Barker, Ubaldo J. Martin   +8 more
doaj   +2 more sources

Sinonasal Outcomes Obtained after 2 Years of Treatment with Benralizumab in Patients with Severe Eosinophilic Asthma and CRSwNP: A “Real-Life” Observational Study

Journal of Personalized Medicine
Background/Objectives: Benralizumab is a monoclonal antibody that targets the interleukin-5 receptor (IL-5Rα), leading to the rapid depletion of blood eosinophils. RCTs have demonstrated efficacy in patients with severe eosinophilic asthma (SEA). The aim
Eugenio de Corso, D. Mele, Angela Rizzi, Camilla Spanu, Marco Corbò, Serena Pisciottano, R. Mastrapasqua, S. Baroni, D. P. Porru, Gabriele De Maio, Alberta Rizzuti, Giuseppe Alberto Di Bella, Augusta Ortolan, M. Bonini, F. Cefaloni, C. Boccabella, Francesco Lombardi, R. Chini, C. Caruso, Marco Panfili, Jacopo Galli   +20 more
semanticscholar   +2 more sources

Benralizumab Reduces Respiratory Exacerbations and Oral Glucocorticosteroid Dose in Patients with Severe Asthma and Eosinophilic Granulomatosis with Polyangiitis

Journal of Asthma and Allergy
Carlo Mümmler,1 Pontus Mertsch,1 Michaela Barnikel,1 Frank Haubner,2 Ulf Schönermarck,3 Ulrich Grabmaier,4 Hendrik Schulze-Koops,5 Jürgen Behr,1 Nikolaus Kneidinger,1,6 Katrin Milger1 1Department of Medicine V, LMU University Hospital, LMU Munich ...
Mümmler C, Mertsch P, Barnikel M, Haubner F, Schönermarck U, Grabmaier U, Schulze-Koops H, Behr J, Kneidinger N, Milger K   +9 more
doaj   +2 more sources

Benralizumab: Effectiveness in Patients with Uncontrolled Severe Eosinophilic Asthma at 6 and 12 Months at a Third-Level Care Hospital. Capacity for ICS-LABA Therapy Reduction. [PDF]

J Asthma Allergy
Background Asthma is a health condition with worldwide relevance, evaluated based on the necessary treatment to control symptoms and exacerbations. Severe asthma is uncontrolled despite high doses of ICS-LABA and treatment for triggering factors.
González-Tuyub YH, González-Iñiguez KD, Lizarazo-Guiza PC, García-García SR.   +3 more
europepmc   +2 more sources

The effect of benralizumab on inflammation in severe asthma: a real-life analysis [PDF]

Therapeutic Advances in Respiratory Disease
Background: Benralizumab is a monoclonal antibody treatment for severe eosinophilic asthma (SEA). Few studies investigated its role in airway inflammation and its correlation with lung function.
Ardesi F., Centis R., Grossi S., Migliori G. B., Pignatti P., Pini L., Sotgiu G., Spanevello A., Vanetti M., Visca D., Zappa M.   +10 more
core   +2 more sources

Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma: a long-term retrospective analysis

Annals medicus
Background Some patients with severe asthma may benefit from treatment with biologics, but evidence has been mostly collected from randomized controlled trials (RCTs), in which patients’ characteristics are different from those encountered in asthma ...
M. Basagaña, Carlos Martínez-Rivera, Clara Padró, Ignasi Garcia-Olivé, Mimar Martínez-Colls, Juan Navarro, Laura Pardo, Paula Cruz, Gloria Cardona Peitx, Lídia Carabias, Albert Roger, Jorge Abad, Antoni Rosell   +12 more
semanticscholar   +2 more sources